6-(4-methylpiperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(1,1,2,2-tetramethylpropylsilanyloxy)phenyl]thieno[3,2-d]pyrimidine | 885616-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 6-(4-methylpiperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(1,1,2,2-tetramethylpropylsilanyloxy)phenyl]thieno[3,2-d]pyrimidine
• CAS: 885616-94-4
• 化学式: C₂₈H₄₁N₅O₂SSi
• 分子量: 539.817
• InChiKey: BJVFSPHQLAMOLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.33
• 重原子数：
  37.0
• 可旋转键数：
  6.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  53.96
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  6-(4-methylpiperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(1,1,2,2-tetramethylpropylsilanyloxy)phenyl]thieno[3,2-d]pyrimidine 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以85%的产率得到SN 30693
  参考文献：
  名称：

  The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

  摘要：

  Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110alpha. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.

  DOI：

  10.1021/jm800295d
• 作为产物：
  描述：

  N-甲基哌嗪 、 4-morpholin-4-yl-2-[3-(1,1,2,2-tetramethylpropylsilanyloxy)phenyl]thieno[3,2-d]pyrimidine-6-carbaldehyde 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 72.0h， 以88%的产率得到6-(4-methylpiperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(1,1,2,2-tetramethylpropylsilanyloxy)phenyl]thieno[3,2-d]pyrimidine
  参考文献：
  名称：

  The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

  摘要：

  Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110alpha. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.

  DOI：

  10.1021/jm800295d